Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Synageva BioPharma Closes $115 Mln Stock Offering

RELATED NEWS
Trade GEVA now with 
7/13/2012 12:56 PM ET

Synageva BioPharma Corp. (GEVA: Quote) said Friday that it has closed a $115 million underwritten public offering of 2,792,200 shares of common stock, including 364,200 shares of common stock which were issued pursuant to the exercise of the underwriters' over-allotment option, at a price of $41.20 per share.

Morgan Stanley and J.P. Morgan acted as joint book-running managers in the offering, and Cowen and Company, Leerink Swann, Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences acted as co-managers in the offering.

Click here to receive FREE breaking news email alerts for Synageva BioPharma Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks moved sharply higher over the course of the trading day on Friday, more than offsetting the weakness seen on Thursday. In a reversal from the previous session, the markets benefited from some upbeat U.S. economic data as well as comments from a Federal Reserve official. The major averages saw further upside going into the close, with the Dow and the S&P 500 reaching new record highs. As the IRS targeting scandal continues to make headlines, animal-protection charity People for the Ethical Treatment of Animals, or PETA, claims that conservative groups are not the only ones that have faced increased scrutiny from the agency. While the IRS targeting scandal has taken center stage on Capitol Hill on Friday, the results of a new Gallup poll showed that the American public's interest in the story is comparatively low based on historical measures. The poll showed that 54 percent of Americans are following the news that the IRS targeted conservative groups for greater scrutiny "very" or "somewhat" closely.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.